Amaro Therapeutics, Inc.
Our discovery platform is focused on the (re)emerging field of chemoreceptors, specifically taste receptors, as therapeutic targets. We are capitalizing on over 10 years of preclinical and clinical experience in the development of disease modifying compounds targeting the modulation of bitter taste receptors. Our discovery engine incorporates a robust compound screening system inclusive of proprietary assays designed to elicit the tissue specific biological function(s) of taste receptor activation. We further incorporate secondary in vitro screening for safety/toxicity as well as integrated in vivo studies to inform high value indications such as diabetes, obesity, and non-alcoholic steatohepatitis. We add to this screening capability a unique understanding of novel compound synthesis of natural product analogs. We generate intellectual property around these capabilities as well as acquiring patents that broaden and protect an innovative discovery platform.